Q-omics provides the consensus-scored DBNDD1 profile across patient tissues and cancer cell-line models. DBNDD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DBNDD1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, DBNDD1 RNA expression shows 16,326 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where DBNDD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DBNDD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DBNDD1 survival associations across molecular data types. DBNDD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DBNDD1 RNA expression–survival associations across cancer types. High DBNDD1 expression shows unfavorable associations in BLCA, ACC and LGG, but favorable associations in KICH, KIRP and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for DBNDD1 RNA expression.
This table summarizes DBNDD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DBNDD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DBNDD1 shows lower tumor expression in HNSC and higher tumor expression in COAD, LUAD, KIRP, LIHC and BRCA. The COAD box plot shows higher DBNDD1 RNA expression in tumor versus normal tissue (log2 FC = +2.302, t-test p < 0.001).
This table shows molecular features associated with DBNDD1 in patient tissues and cancer cell lines. In patient samples, DBNDD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DBNDD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
